Avedro Secures $43,000,000 Series D Funding
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=6d6a3b0a-e930-4a37-8089-785bc8f9a578&Preview=1 - Date
3/6/2013 - Company Name
Avedro - Mailing Address
230 Third Avenue Waltham, MA 02451 - Company Description
Avedro’s Keraflex is not laser eye surgery – it is a non-incisional, non-invasive procedure currently under clinical study for the correction of myopia and the treatment of keratoconus. Unlike LASIK and other laser vision correction procedures, Keraflex offers peace of mind because it does not cut a flap in the cornea nor does it remove any corneal tissue. Evidence suggests this approach will preserve the all important bio-mechanical integrity of the cornea. - Website
http://www.avedro.com - Transaction Type
Venture Equity - Transaction Amount
$43,000,000 - Transaction Round
Series D - Proceeds Purposes
Proceeds from this financing will allow us to execute on both our global commercialization strategy and our US FDA approval strategy. - M&A Terms
- Venture Investor
Abingworth Management - Venture Investor
Third Point - Venture Investor
Undisclosed
